Avacta Announces Year-end Trading Update

LONDON and PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, has published a trading update for the year ended December 31, 2025. The Company made excellent progress during 2025, developing its unique industry-leading technology platform, pre|CISION®, with two programs anticipated to be in clinical development in 2026. The Company raised £22.5m in equity during 2025 ...